Novo Nordisk Takes Legal Action Against Eli Lilly To Stop Multiple Misleading National GLP-1 Advertising Campaigns
Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli LillyA lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses
Novo Nordisk is suing Eli Lilly, saying Eli Lilly's ads about weight-loss medicine are tricking people. When companies fight in court like this, it can hint at how serious they think the competition is.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.